Does BPC 157 Cause Cancer?

Your body is constantly building new blood vessels, and it does this using a signaling molecule called VEGF, which stands for vascular endothelial growth factor and works essentially like a construction order that tells your vascular system where to send new pipes.

When tissue is damaged, whether from a torn tendon or a blocked artery, the injured cells release VEGF, and that signal binds to receptors on the walls of nearby blood vessels and tells them to branch out toward the damage. More vessels means more oxygen, more nutrients, and faster repair.

BPC-157 works by amplifying one specific part of this system. It increases the number of VEGF receptors on cell surfaces, specifically a receptor called VEGFR2, which is the primary one responsible for triggering new vessel growth. More receptors means the tissue becomes more sensitive to VEGF signals that are already circulating, so the angiogenic response, meaning the process of building new blood vessels, happens faster and more completely. A 2017 study in rats with hind limb ischemia showed that BPC-157 activated the VEGFR2-Akt-eNOS signaling chain and measurably increased vessel density in ischemic tissue compared to controls. That is the mechanism behind the healing effects people report.

Here is where the concern enters.

Tumors use the exact same pathway. When a solid tumor grows past a certain size, usually around one to two millimeters, it can no longer get enough oxygen by passive diffusion from nearby vessels. So it starts secreting VEGF on its own, essentially sending out the same construction orders your injured tendon sends, because it needs its own blood supply to keep growing.

This is not a coincidence or a quirk of tumor biology. Cancer cells co-opt normal repair and growth mechanisms because those mechanisms are the most efficient tools available in the cellular environment. The VEGF pathway is one of the most well-characterized examples of this. And it is exactly why one of the more successful classes of cancer drugs works by blocking VEGF signaling entirely, because cutting off a tumor's blood supply starves it.

So if BPC-157 is upregulating VEGFR2 and making cells more responsive to VEGF signals, the theoretical question is whether it could accelerate that same process in a tumor someone does not know they have.

The honest answer is that we do not know.

There is one study that looked at BPC-157 and cancer cells directly. It was published in 2004 as a conference abstract, testing the compound against a human melanoma cell line called SK-Mel-1, and it found that BPC-157 actually reduced the fraction of cells in active division by up to 55% at concentrations of 2 nanograms and 10 nanograms. That result would suggest an inhibitory effect rather than a stimulating one.

But that study has never been independently replicated in over 20 years. It was not published as a full peer-reviewed paper. It was conducted by researchers affiliated with the same lab that has produced the majority of BPC-157 research. And critically, it tested isolated cancer cells in a dish, not a tumor in a living organism where vessel supply, immune function, and tissue architecture all interact.

There is also a separate pathway worth naming. BPC-157 activates something called FAK-paxillin signaling, which is a pathway involved in how cells anchor to surfaces and migrate through tissue. In normal physiology, this supports wound healing by helping new cells move into damaged areas. In cancer biology, FAK-paxillin signaling is associated with cancer cell invasion and metastasis, which is the process by which cancer cells spread from the original tumor to other sites in the body. Whether BPC-157's activation of this pathway has any meaningful effect on cancer progression in a living system has not been studied.

A 2025 published commentary in Pharmaceuticals reviewed the available evidence and concluded that there is no published in vivo data demonstrating that BPC-157 either promotes or inhibits tumor progression, reduces tumor volume, or suppresses metastasis in any animal or human model. The field is operating almost entirely from mechanistic inference and one unreplicated in vitro result.

That is the actual state of the evidence.

The question then becomes what to do with mechanistic concern in the absence of direct evidence. The answer depends on what you are optimizing for.

For someone with no cancer history and no known precancerous conditions, the theoretical risk from BPC-157's angiogenic mechanism is exactly that, theoretical, and it sits alongside a body of animal data showing tissue repair benefits that have not translated into documented cancer promotion across the many years this compound has been studied informally. That does not make it safe. It means the signal, if there is one, is not large enough to have shown up clearly yet in the data we have.

For someone with active cancer, a history of cancer, or conditions that carry elevated cancer risk, the calculus is different. Amplifying VEGF sensitivity in a system that may already have cells attempting to recruit blood supply is a risk profile that does not make sense to accept for a compound that is still investigational, that has no approved clinical use, and for which there is no human trial data at all.

The most important thing to understand is that the absence of evidence that BPC-157 causes cancer is not the same as evidence that it does not. Those are different statements, and conflating them in either direction, either to dismiss the concern or to declare the compound dangerous, misrepresents what the science actually shows.

What the science actually shows is a mechanism that warrants caution in specific populations, a single unreplicated cell study that cannot support firm conclusions in either direction, and a compound that has never been tested in a living organism with an actual tumor.

The gap between "this pathway is involved in cancer" and "this compound causes cancer" is exactly the size of the research that has not been done yet.

---

References

1. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. Study conditions: Rat hind limb ischemia model and human umbilical vein endothelial cell cultures. Did not test tumor models. Finding: BPC-157 increased VEGFR2 expression and activated the VEGFR2-Akt-eNOS signaling pathway, increasing vessel density in ischemic tissue.
2. Radeljak S, Seiwerth S, et al. BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line. Melanoma Research. 2004;14(4):A14-A15 (conference abstract). Study conditions: In vitro, SK-Mel-1 human melanoma cells at 2ng and 10ng concentrations. Authored by Sikiric-affiliated researchers. Never independently replicated. Finding: BPC-157 lowered total S-phase fraction (cell division) up to 55% in SK-Mel-1 melanoma cells compared to controls.
3. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025;18(10):1451. Published commentary (not original research). Finding: No published in vivo data demonstrate that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis. The Radeljak 2004 study remains unreplicated. BPC-157 activates FAK-paxillin signaling, a known pathway in cancer cell invasion.
4. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619. Finding: BPC-157 should be considered investigational until well-designed human trials are conducted and published.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness